Physician profile
Jeffrey Sweeney
NPI 1750479465
$1,793.52
in general payments reported to CMS, 2019-2025
29 companies · $527 in 2025
The $527 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $255 · 2020: $105 · 2021: $102 · 2022: $138 · 2023: $238 · 2024: $429 · 2025: $527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,193.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $444.09 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $164.24 | 2021-2024 | Freestyle Libre 3 |
| Amgen INC. | $156.26 | 2024-2025 | Repatha, Otezla, Repatha |
| Inspire Medical Systems, INC. | $129.56 | 2024-2025 | Inspire |
| Astellas Pharma US INC | $114.23 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $88.87 | 2022-2023 | Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $85.79 | 2021-2024 | |
| Boston Scientific Corporation | $79.74 | 2020-2021 | |
| Stryker Corporation | $58.64 | 2024 | Augment Injectable |
| Vertiflex, INC. | $57.90 | 2019 | |
| Abbvie INC. | $45.30 | 2022-2023 | Vraylar |
| Pfizer INC. | $34.58 | 2019-2020 | |
| Lilly USA, LLC | $34.11 | 2022-2024 | Mounjaro |
| Irhythm Technologies, INC. | $32.37 | 2023 | Zio Xt Patch |
| Shire North American Group INC | $27.64 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $23.01 | 2020 | |
| Hologic Sales and Service, LLC | $22.69 | 2025 | Aptima |
| Ironshore Pharmaceuticals INC. | $21.62 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.64 | 2019 | |
| Phathom Pharmaceuticals, INC. | $18.42 | 2024 | Voquezna |
| Si-Bone, INC. | $17.12 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.78 | 2019 | |
| Currax Pharmaceuticals LLC | $16.58 | 2025 | Contrave |
| Sanofi-Aventis U.S. LLC | $15.79 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.17 | 2020 | |
| Amarin Pharma, INC. | $14.47 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.20 | 2019 | |
| Supernus Pharmaceuticals, INC. | $14.14 | 2025 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $11.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Sweeney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.